With US Government support, MIIST305 is also being developed in parallel as a medical countermeasure (MCM) for gastrointestinal acute radiation syndrome (GI-ARS).

This contract aims to develop Synedgen’s lead therapeutic, MIIST305, to address Gastrointestinal Acute Radiation Syndrome (GI-ARS) arising from acute exposure to ionizing radiation.

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced the publication of preclinical data that shows MIIST305 mitigating ...

The disease is also known as Acute Radiation Syndrome (ARS) ... Researchers in Tennessee have said they are working on the first-ever drug that could treat gastrointestinal radiation sickness, ...

Background: To predict acute toxicities (tox) of the gastrointestinal syndrome (SOMA LENT) in prostate cancer (PCa) patients (pts) undergoing 3D-CRT using a tool (nomogram) with clinical as well as ...

Catastrophic radiological events — like nuclear detonations — can threaten massive populations with acute radiation syndrome, which wreaks havoc on the gastrointestinal system and destroys ...

The gastrointestinal tract is one of the first organs injured by radiation, but no FDA-approved treatments exist for gastrointestinal acute radiation syndrome.

Rubin and colleagues published the results of their studies in STEM CELLS Translational Medicine, in a paper titled “Allogeneic adipose-derived stem cells mitigate acute radiation syndrome by ...

IMPREPLYS would be indicated for treatment of patients of all ages acutely exposed to myelosuppressive doses of radiation with Haematopoietic Sub-syndrome of Acute Radiation Syndrome (H-ARS).

Exposure to high-dose radiation can result in gastrointestinal (GI) acute radiation syndrome, which is characterized by disruption of the mucosal layer, intestinal epithelial barrier dysfunction, and ...

LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...